PancraGEN to Remain Available as Interpace Re-evaluates Restructuring Plan
Interpace Diagnostics® Announces Delay in Medicare Coverage Determination Parsippany, NJ, Jan. 27, 2025 (GLOBE NEWSWIRE) Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced notification that the Centers for Medicare & Medicaid Services (CMS) directed its Medicare Administrative Contractors, Novitas and First Coast Service Options, Inc., to delay implementation…